Anti-CLDN18 Products

Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag

Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us

For Research Use Only. Not For Clinical Use.

Creative Biolabs is your trusted partner in immuno-oncology. We provide you with premium anti-CLDN18 recombinant antibodies (rAbs) for one of the most promising targets in gastric and pancreatic cancer today. Claudin-18 (CLDN18), specifically the stomach-specific isoform of the protein known as CLDN18.2, has been identified as a new and highly specific target for gastric and pancreatic cancers. We offer high-quality, isoform-specific antibodies to help you validate this target and to work towards the next generation of cancer treatments that target CLDN18, including next-gen monoclonal antibodies as well as CAR-T cells.

CLDN18: A Key Target in Gastric and Pancreatic Cancer

Claudin-18 (CLDN18) is a tight junction membrane protein that exists as two isoforms. One is specific to the lung (CLDN18.1), while the other (CLDN18.2) is expressed almost exclusively in the differentiated epithelial cells of the gastric mucosa. During gastric (but also pancreatic and esophageal) adenocarcinoma development, this tight junction architecture is disrupted, exposing CLDN18.2 on the cell surface and making it available as an accessible, highly specific tumor antigen. This protein is essentially expressed only on malignant cells (with the exception of its expression in the healthy stomach), making it an attractive target for highly specific, tumor-directed therapies.

Alternative Names

SFTA5; SFTPJ; claudin-18; surfactant associated 5; surfactant associated protein J; surfactant, pulmonary associated protein J

Background

This gene encodes a member of the claudin family. Claudins are integral membrane proteins and components of tight junction strands. Tight junction strands serve as a physical barrier to prevent solutes and water from passing freely through the paracellular space between epithelial or endothelial cell sheets, and also play critical roles in maintaining cell polarity and signal transductions. This gene is upregulated in patients with ulcerative colitis and highly overexpressed in infiltrating ductal adenocarcinomas. PKC/MAPK/AP-1 (protein kinase C/mitogen-activated protein kinase/activator protein-1) dependent pathway regulates the expression of this gene in gastric cells. Alternatively spliced transcript variants encoding different isoforms have been identified.

Anti-CLDN18 rAb Products

Our anti-CLDN18 recombinant antibodies are designed to have high isoform specificity and are fine-tuned to recognize the clinically relevant CLDN18.2 isoform. We validate our rAbs for recognition of the native protein at the cell surface to ensure you have a product that will perform well in the appropriate assays for your work, whether that’s flow cytometry, IHC on tumor biopsies, or use as a reference for CAR-T or antibody-drug conjugate (ADC) development.

Table 1. Featured anti-CLDN18 recombinant antibody products at Creative Biolabs.

Creative Quality Control

Creative Biolabs’ production of our immuno-oncology reagents is backed by our extensive quality control program. Every lot of our anti-CLDN18.2 antibody is thoroughly validated for purity, binding affinity, and absolute specificity against other claudins such as CLDN18.1. This ensures you have a reliable, high-performance reagent that can be used for even the most demanding applications in therapeutic development and companion diagnostics.

Customer Reviews

rAb Production

With strong demand for this therapeutic target, Creative Biolabs has produced these antibodies in high quantities. Our cutting-edge mammalian expression platforms mean that our anti-CLDN18 recombinant antibodies have the proper folding and post-translational modifications to recognize the intricate extracellular loops of the native protein, which is critical to strong affinity and high specificity.

Featured Anti-CLDN18 Recombinant Antibody Production Platforms
Fig.4 Milligram-scale anti-CLDN18 recombinant antibody production.

Fig.5 Gram-scale anti-CLDN18 recombinant antibody production.

rAb Modalities

Creative Biolabs’ portfolio of anti-CLDN18.2 antibodies includes all modalities to power your work. We offer you our customizable antibodies, including full-length human IgGs for ADCC/CDC assays, as well as antibody fragments such as scFv and Fab to work into your CAR-T constructs or bispecific antibodies for researchers around the world.

Fig.6 Full-length anti-CLDN18 recombinant antibody production and modalities.

CLDN18-Targeted Drug Information

Table 2. Public drug targeting CLDN18.

(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)

Power your gastric cancer therapeutic program with Creative Biolabs’ high-quality, recombinant antibodies that target CLDN18.2. We offer the high specificity, extensive validation, and format flexibility required for this new and highly specific target. Collaborate with Creative and ensure your research has a solid foundation of quality. Contact our experts today to get started.